Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

TB diagnostic based on antigens from M. tuberculosis

a technology of tuberculosis and diagnostics, applied in the field of new antigens, can solve the problems of inability to demonstrate significant protection in clinical trials in developing countries, inability to approve bcg, and inability to demonstrate a specific long-term protective immune response with the potency of bcg

Inactive Publication Date: 2004-06-17
STATENS SERUM INST
View PDF0 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

BCG generally induces a high level of acquired resistance in animal models of TB, but several human trials in developing countries have failed to demonstrate significant protection.
Notably, BCG is not approved by the FDA for use in the United States.
However, the demonstration of a specific long-term protective immune response with the potency of BCG has not yet been achieved by administration of soluble proteins or cell wall fragments, although progress is currently being made by relying on polypeptides derived from short term-culture filtrate, cf. the discussion below.
Culture filtrates are, however, complex protein mixtures and until now very limited information has been available on the molecules responsible for this protective immune response.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • TB diagnostic based on antigens from M. tuberculosis
  • TB diagnostic based on antigens from M. tuberculosis
  • TB diagnostic based on antigens from M. tuberculosis

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0173] Identification of Single Culture Filtrate Antigens Involved in Protective Immunity

[0174] A group of efficiently protected mice was generated by infecting 8-12 weeks old female C57Bl / 6j mice with 5.times.10.sup.4 M. tuberculosis i.v. After 30 days of infection the mice were subjected to 60 days of antibiotic treatment with isoniazid and were then left for 200-240 days to ensure the establishment of resting long-term memory immunity. Such memory immune mice are very efficiently protected against a secondary infection (FIG. 1). Long lasting immunity in this model is mediated by a population of highly reactive CD4 cells recruited to the site of infection and triggered to produce large amounts of IFN-.gamma. in response to ST-CF (FIG. 1) (Andersen et al. 1995).

[0175] We have used this model to identify single antigens recognized by protective T cells. Memory immune mice were reinfected with 1.times.10.sup.6 M. tuberculosis i.v. and splenic lymphocytes were harvested at day 4-6 of ...

example 2

[0176] Cloning of Genes Expressing Low Mass Culture Filtrate Antigens

[0177] In example 1 it was demonstrated that antigens in the low molecular mass fraction are recognized strongly by cells isolated from memory immune mice. Monoclonal antibodies (mAbs) to these antigens were therefore generated by immunizing with the low mass fraction in RIBI adjuvant (first and second immunization) followed by two injections with the fractions in aluminium hydroxide. Fusion and cloning of the reactive cell lines were done according to standard procedures (Kohler and Milstein 1975). The procedure resulted in the provision of two mAbs: ST-3 directed to a 9 kDa culture filtrate antigen (CFP9) and PV-2 directed to a 7 kDa antigen (CFP7), when the molecular weight is estimated from migration of the antigens in an SDS-PAGE.

[0178] In order to identify the antigens binding to the Mab's, the following experiments were carried out:

[0179] The recombinant .lambda.gt11 M. tuberculosis DNA library constructed b...

example 2a

[0214] Identification of Antigens which are not Expressed in BCG Strains.

[0215] In an effort to control the treat of TB, attenuated bacillus Calmette-Gurin (BCG) has been used as a live attenuated vaccine. BCG is an attenuated derivative of a virulent Mycobacterium bovis. The original BCG from the Pasteur Institute in Paris, France was developed from 1908 to 1921 by 231 passages in liquid culture and has never been shown to revert to virulence in animals, indicating that the attenuating mutation(s) in BCG are stable deletions and / or multiple mutations which do not readily revert. While physiological differences between BCG and M. tuberculosis and M. bovis has been noted, the attenuating mutations which arose during serial passage of the original BCG strain has been unknown until recently. The first mutations described are the loss of the gene encoding MPB64 in some BCG strains (Li et al., 1993, Oettinger and Andersen, 1994) and the gene encoding ESAT-6 in all BCG strain tested (Harb...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
massaaaaaaaaaa
diameteraaaaaaaaaa
concentrationsaaaaaaaaaa
Login to View More

Abstract

The present invention is based on the identification and characterization of a number of M. tuberculosis derived novel proteins and protein fragments (SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 17-23, 42, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72-86, 88, 90, 92, 94, 141, 143, 145, 147, 149, 151, 153, and 168-171). The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as vaccines and skin test reagents containing the polypeptides. Another part of the invention is based on the surprising discovery that fusions between ESAT-6 and MPT59 are superior immunogens compared to each of the unfused proteins, respectively.

Description

[0001] The present invention relates to a number of immunologically active, novel polypeptide fragments derived from the Mycobacterium tuberculosis, vaccines and other immunologic compositions containing the fragments as immunogenic components, and methods of production and use of the polypeptides. The invention also relates to novel nucleic acid fragments derived from M. tuberculosis which are useful in the preparation of the polypeptide fragments of the invention or in the diagnosis of infection with M. tuberculosis. The invention further relates to certain fusion polypeptides, notably fusions between ESAT-6 and MPT59.[0002] Human tuberculosis (hereinafter designated "TB") caused by Mycobacterium tuberculosis is a severe global health problem responsible for approximately 3 million deaths annually, according to the WHO. The worldwide incidence of new TB cases has been progressively falling for the last decade but the recent years has markedly changed this trend due to the advent o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/00A61K39/00C07K14/35
CPCA61K38/00A61K39/00C07K2319/00C07K14/35A61K2039/51A61P31/06
Inventor ANDERSEN, PETERSKIOT, RIKKEOETTINGER, THOMASRASMUSSEN, PETER BIRKROSENKRANDS, IDAWELDINGH, KARINFLORIO, WALTER
Owner STATENS SERUM INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com